Array BioPharma (ARRY) reported 44% jump in second-quarter revenue to $82.5 million, driven by higher product sales and recognition of $40 million of milestone revenue from Loxo Oncology. The top line came in well above street projection of $49.02 million.
Net loss was cut down to 5 cents per share from 17 cents per share last year. Analysts were expecting a loss of 16 cents per share.
ARRY shares popped 3.2% during pre-market trading post the earnings announcement. The stock has gained 35% in the trailing 12 months.
CEO Ron Squarer said, “We continue to be pleased with demand following the US launch of BRAFTOVI + MEKTOVI for patients with BRAF-mutant metastatic melanoma, which delivered $22.7 million in net product sales during the second commercial quarter.”
BRAFTOVI + MEKTOVI net product sales soared 62% in the US compared to the prior sequential quarter. The combination has also been launched in Germany, Austria, the Netherlands, and the United Kingdom
Video game company Electronic Arts, Inc. (NASDAQ: EA) reported lower earnings and revenues for the fourth quarter of 2021. Earnings also missed analysts' forecast. During the March quarter, net bookings
Shares of Tyson Foods Inc. (NYSE: TSN) were in green territory during afternoon hours on Tuesday. The stock has gained 32% over the past 12 months and 23% since the
Space tourism company Virgin Galactic Holdings, Inc. (NYSE: SPCE) ended the first quarter of 2021 without generating revenue and continued the losing streak even as uncertainty over its test flight